Daymark Wealth Partners LLC Trims Stock Holdings in Pfizer Inc. (NYSE:PFE)

Daymark Wealth Partners LLC reduced its stake in Pfizer Inc. (NYSE:PFE - Free Report) by 9.4% during the 1st quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 243,733 shares of the biopharmaceutical company's stock after selling 25,397 shares during the quarter. Daymark Wealth Partners LLC's holdings in Pfizer were worth $6,176,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently modified their holdings of the company. Lecap Asset Management Ltd. raised its holdings in Pfizer by 20.9% in the 1st quarter. Lecap Asset Management Ltd. now owns 81,193 shares of the biopharmaceutical company's stock valued at $2,057,000 after acquiring an additional 14,050 shares during the period. Horizon Bancorp Inc. IN increased its stake in Pfizer by 1.0% in the first quarter. Horizon Bancorp Inc. IN now owns 69,047 shares of the biopharmaceutical company's stock valued at $1,750,000 after acquiring an additional 664 shares during the last quarter. International Assets Investment Management LLC lifted its position in shares of Pfizer by 4.3% during the 1st quarter. International Assets Investment Management LLC now owns 235,121 shares of the biopharmaceutical company's stock worth $5,495,000 after buying an additional 9,630 shares during the last quarter. Embree Financial Group boosted its stake in Pfizer by 29.1% in the first quarter. Embree Financial Group now owns 12,524 shares of the biopharmaceutical company's stock valued at $317,000 after buying an additional 2,826 shares in the last quarter. Finally, Keudell Morrison Wealth Management raised its stake in Pfizer by 13.4% during the first quarter. Keudell Morrison Wealth Management now owns 18,110 shares of the biopharmaceutical company's stock worth $459,000 after acquiring an additional 2,147 shares in the last quarter. 68.36% of the stock is owned by institutional investors and hedge funds.

Pfizer Stock Performance

Shares of NYSE:PFE traded down $0.02 during midday trading on Wednesday, reaching $24.29. The company had a trading volume of 25,591,071 shares, compared to its average volume of 41,231,236. The stock has a market cap of $138.10 billion, a P/E ratio of 17.60, a P/E/G ratio of 0.87 and a beta of 0.57. The company's 50 day moving average price is $23.33 and its 200 day moving average price is $24.87. The company has a current ratio of 1.26, a quick ratio of 0.96 and a debt-to-equity ratio of 0.64. Pfizer Inc. has a 52-week low of $20.92 and a 52-week high of $31.54.

Pfizer (NYSE:PFE - Get Free Report) last released its earnings results on Tuesday, April 29th. The biopharmaceutical company reported $0.92 earnings per share for the quarter, beating analysts' consensus estimates of $0.67 by $0.25. Pfizer had a net margin of 12.62% and a return on equity of 20.33%. The firm had revenue of $13.72 billion for the quarter, compared to analysts' expectations of $14.43 billion. During the same period in the previous year, the company earned $0.82 earnings per share. The company's quarterly revenue was down 7.8% on a year-over-year basis. As a group, sell-side analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, June 13th. Shareholders of record on Friday, May 9th were given a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 7.08%. The ex-dividend date of this dividend was Friday, May 9th. Pfizer's dividend payout ratio is currently 124.64%.

Analyst Ratings Changes

Several equities research analysts recently weighed in on the company. Guggenheim reissued a "buy" rating on shares of Pfizer in a report on Tuesday, March 18th. UBS Group raised their price objective on shares of Pfizer from $24.00 to $25.00 and gave the stock a "neutral" rating in a research report on Wednesday, April 30th. Hsbc Global Res upgraded shares of Pfizer to a "strong-buy" rating in a research report on Monday, March 10th. Cantor Fitzgerald started coverage on shares of Pfizer in a report on Tuesday, April 22nd. They issued a "neutral" rating and a $24.00 price target for the company. Finally, Citigroup reaffirmed a "neutral" rating on shares of Pfizer in a research note on Thursday, March 27th. One analyst has rated the stock with a sell rating, eight have issued a hold rating, four have issued a buy rating and three have issued a strong buy rating to the company. According to MarketBeat, the stock has a consensus rating of "Moderate Buy" and an average price target of $29.17.

Pfizer Profile

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.